Skip to main content

Table 5 Predictors of Recurrent Restenosis within 5 Years after Treatment of In-stent Restenosis in the Matched Population

From: Long-term clinical effectiveness of a drug-coated balloon for in-stent restenosis in Femoropopliteal lesions

Variables Univariable Multivariable
HR 95% CI p HR 95% CI p
Age, (per 1 year) 1.03 0.92–1.03 0.343    
Male sex 1.40 0.60–3.55 0.460    
Body mass index (per 1.0) 0.99 0.89–1.10 0.835    
Dyslipidemia 0.83 0.37–1.80 0.640    
Diabetes mellitus 1.24 0.51–2.77 0.618    
Current smoker 1.58 0.61–3.64 0.324    
Chronic kidney disease 1.52 0.65–4.16 0.351    
Hemodialysis 1.12 0.18–3.78 0.881    
Use of cilostazol 1.30 0.60–2.91 0.505    
Involvement of popliteal lesion 1.51 0.59–3.44 0.370    
Reference vessel diameter (per 1.0 mm) 0.96 0.40–2.43 0.925    
ISR length (per 10.0 mm) 1.04 0.98–1.10 0.172 1.04 0.97–1.10 0.251
Tosaka type III (occlusion) 2.10 0.85–4.73 0.102 1.39 0.55–3.23 0.463
PACSS grade 4 of native lesions 1.05 0.40–3.58 0.933    
Tibial runoff ≤1 1.65 0.72–3.61 0.224    
Use of PCB at ISR treatment 0.16 0.06–0.39 < 0.001 0.17 0.06–0.41 < 0.001
  1. CI indicates confidence interval, HR hazard ratio, ISR in-stent restenosis, PACSS Proposed Peripheral Arterial Calcium Scoring System, PCB paclitaxel-coated balloon